[go: up one dir, main page]

BR112019006506A2 - comprimidos compreendendo 2-hi¬dróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi) benzaldeído - Google Patents

comprimidos compreendendo 2-hi¬dróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi) benzaldeído

Info

Publication number
BR112019006506A2
BR112019006506A2 BR112019006506A BR112019006506A BR112019006506A2 BR 112019006506 A2 BR112019006506 A2 BR 112019006506A2 BR 112019006506 A BR112019006506 A BR 112019006506A BR 112019006506 A BR112019006506 A BR 112019006506A BR 112019006506 A2 BR112019006506 A2 BR 112019006506A2
Authority
BR
Brazil
Prior art keywords
tablets
pyrazol
benzaldehyde
pyridin
methoxy
Prior art date
Application number
BR112019006506A
Other languages
English (en)
Other versions
BR112019006506B1 (pt
Inventor
Komeyli Ali
Leung Demei
Bejugam Naveen
Habibizad Nazila
Mark Dalziel Sean
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60183140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019006506(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of BR112019006506A2 publication Critical patent/BR112019006506A2/pt
Publication of BR112019006506B1 publication Critical patent/BR112019006506B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a comprimidos de alta potência/alta carga de fármaco compreendendo 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído ("composto 1"), comprimidos dispersíveis compreendendo o composto 1, processos de fabricação dos referidos comprimidos, e métodos para tratar os pacientes com os comprimidos. o composto 1 é útil para tratar distúrbios hematológicos tais como doença falciforme, doença pulmonar tal como fibrose pulmonar idiopática e condições de hipoxia e hipoxemia.
BR112019006506-7A 2016-10-12 2017-10-12 Comprimidos compreendendo 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il) piridin-3-il)metóxi) benzaldeído e uso dos mesmos BR112019006506B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407406P 2016-10-12 2016-10-12
US62/407,406 2016-10-12
US201762553716P 2017-09-01 2017-09-01
US62/553,716 2017-09-01
PCT/US2017/056352 WO2018071678A1 (en) 2016-10-12 2017-10-12 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Publications (2)

Publication Number Publication Date
BR112019006506A2 true BR112019006506A2 (pt) 2019-06-25
BR112019006506B1 BR112019006506B1 (pt) 2024-11-19

Family

ID=

Also Published As

Publication number Publication date
MX2019004120A (es) 2019-08-12
US20240423920A1 (en) 2024-12-26
TW202332423A (zh) 2023-08-16
WO2018071678A1 (en) 2018-04-19
IL265777A (en) 2019-06-30
US20180125789A1 (en) 2018-05-10
MA46522A (fr) 2019-08-21
EP4461357A2 (en) 2024-11-13
TWI778983B (zh) 2022-10-01
TW201815384A (zh) 2018-05-01
US10493035B2 (en) 2019-12-03
EP3525766A1 (en) 2019-08-21
IL296014A (en) 2022-10-01
US20210283061A1 (en) 2021-09-16
MX2023004255A (es) 2023-04-25
EP4461357A3 (en) 2025-02-12
IL265777B2 (en) 2023-02-01
IL265777B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
HUS2200046I1 (hu) Benzamidszármazékok ABL1, ABL2 és BCR-ABL1 aktivitás gátlására
MX2023004255A (es) Comprimidos que comprenden 2-hidroxi-6-((2-(1-isopropil-1h-pirazol -5-il)piridin-3-il)metoxi)benzaldehido.
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
BR112017012402A2 (pt) derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg
BR112014012129A2 (pt) inibidores heterocíclicos de glutaminase
BR112014027406A2 (pt) composto, composição, método de inibição da atividade de amina oxidase aoss/pav-1, método de tratamento de uma doença associada com ou modulada por aoss/pav-1 e uso de um composto
BR112015027114A2 (pt) novos compostos para os inibidores seletivos de histona desacetilase, e composição farmacêutica compreendendo os mesmos
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112018011969A2 (pt) compostos heteroaromáticos como inibidores de btk
CR10455A (es) Compuestos farmaceuticos
EA201200728A1 (ru) Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат
BR112014029139A8 (pt) compostos inibidores da atividade de catecol o-metiltransferase
CY1120008T1 (el) Βενζαμιδια
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
BR112014007223A2 (pt) derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112015011898A2 (pt) forma cristalina a da chidamida, método para preparar a forma cristalina a da chidamida, uso da forma cristalina a da chidamida, forma cristalina b da chidamida, método para preparar a forma cristalina b da chidamida, uso da forma cristalina b da chidamida e formulação farmacêutica para o tratamento de doenças relacionadas à diferenciação e proliferação celular
BR112019002007A2 (pt) composições farmacêuticas, processo para a fabricação de grânulos, processo para a fabricação de uma composição farmacêutica, processo para a preparação de monocloridrato de ipatasertib amorfo, método para o tratamento de distúrbios hiperproliferativos, utilização de uma composição farmacêutica e presente invenção
WO2012112447A3 (en) Histone deacetylase inhibitors and methods of use thereof
CL2013000929A1 (es) Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.
BR112014009297A2 (pt) processos para a preparação de 6-cloro-2,3,4,9-tetrahidro-1 h-carbazol-1-carboxamida e dos seus precursores

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GLOBAL BLOOD THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/10/2017, OBSERVADAS AS CONDICOES LEGAIS